NF2 and schwannoma: These data demonstrate an effective systems biology approach for preclinical therapeutic discovery applicable to rare tumors and support the advancement of brigatinib, as a multi-TKI into clinical trials for the treatment of NF2 associated meningiomas and schwannomas.